This newsletter presents you the following key sessions:
1. Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or
interval cytoreductive surgery after neoadjuvant chemotherapy
2. Adagrasib is superior to docetaxel in previously treated patients with KRASG12C-mutated advanced
non-small cell lung cancer
3. Osimertinib following definitive chemoradiotherapy as the new standard of care for patients with
unresectable, stage III, EGFR-mutant NSCLC
4. Trastuzumab-deruxtecan significantly delays disease progression in chemotherapy-naïve patients with
HER2-low and -ultralow, HR+ metastatic breast cancer
![Verzenios](/images/ASCO2024/Verzenios.jpg)
![Opdivo](/images/ASCO2024/Opdivo.jpg)
![Astrazeneca Enhertu footer](/images/ASCO2024/Astrazeneca-Enhertu-footer.jpg)